Ferring Loses Bid To Halt Ads For Watson Fertility Drug

Law360, New York (April 4, 2013, 7:27 PM EDT) -- Ferring Pharmaceuticals Inc. on Thursday lost its bid to stop a Watson Pharmaceuticals Inc. fertility drug advertising campaign it alleges contains shoddy opinion polls and inaccurate effectiveness claims when a New Jersey federal judge ruled Ferring hasn't adequately proved it's been harmed.

U.S. District Judge Dennis M. Cavanaugh said Ferring hasn't proved it's been irreparably harmed by Watson's statements that its vaginal progesterone gel, Crinone, produces more pregnancies and is safer and more convenient than Ferring's vaginal capsule, Endometrin, denying its motion for a preliminary injunction,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.